CSD1603: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From 100s Menthol Cigarette Products

NCT ID: NCT03063047

Last Updated: 2017-03-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-06
• Study Completion Date: 2017-03-13

Brief Summary

This study will evaluate exposure to "tar" and nicotine from two menthol cigarette products and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette products. Mouth-level exposure is the measurement of substance trapped in the cigarette butt after smoking the cigarette.

Other purposes of this study are to:

• Compare the plasma cotinine, a byproduct of your body's processing of nicotine, levels found in users after smoking each of two different cigarettes.
• Find out the daily mouth-level exposure to cigarette "tar" and nicotine from smoking each of two different cigarettes in adult smokers.
• Determine if certain measures of nicotine dependence change based on the type of cigarette smoked
• To compare product liking and intent to use it again.

Detailed Description

The study will consist of one group of approximately 32 adult subjects randomly assigned to the order in which they will smoke two study menthol cigarette products (including one comparator product and one test product). Subjects will smoke each study product exclusively for approximately one week prior to a test visit, with a different product smoked each week over a two-week period. Cigarette butts will be collected the day prior to each test visit for determination of MLE "tar" and nicotine levels. Blood samples will be collected at each test visit for determination of plasma cotinine levels. Subjects will provide responses to questions during each test visit to assess their cigarette smoking and cigarette butt collection behavior during the preceding day.

Conditions

Smoking

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

PD21871AA, PD21872AA

Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.

Group Type: ACTIVE_COMPARATOR

PD21871AA

Intervention Type: OTHER

A 100s size menthol cigarette.

PD21872AA

Intervention Type: OTHER

A 100s size menthol cigarette.

PD21872AA, PD21871AA

Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.

Group Type: ACTIVE_COMPARATOR

PD21871AA

Intervention Type: OTHER

A 100s size menthol cigarette.

PD21872AA

Intervention Type: OTHER

A 100s size menthol cigarette.

Interventions

PD21871AA

A 100s size menthol cigarette.

Intervention Type: OTHER

PD21872AA

A 100s size menthol cigarette.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Able to read, understand, and willing to sign an Informed Consent Form (ICF).
• Generally healthy males and females, 21 years of age or older, at Screening-Enrollment Visit.
• Self-reports smoking at least seven cigarettes per day and inhaling the smoke.
• Usual brand of cigarette is one of the brand styles specified.
• Smoked usual brand for ≥ 3 months.
• Agrees to exclusively smoke the study cigarettes and not smoke or use any other tobacco or nicotine-containing products during the course of the study.
• Able to read and comprehend English.
• Able to safely perform the required study procedures, as determined by the Investigator.

Exclusion Criteria

• Self-reported history of heart disease, kidney disease, asthma or any other lung disease, diabetes, liver disease, hypertension, or hypercholesterolemia.
• At risk for heart disease, i.e., obesity (body mass index [BMI] ≥ 40 kg/m2), as determined by the Investigator.
• Females ≥ 35 years of age currently using systemic, estrogen-containing contraception, or hormone replacement therapy.
• Postponing a decision to quit smoking (defined as planning a quit attempt within 30 days of the Screening-Enrollment Visit) to participate in this study.
• Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days prior to the Screening-Enrollment Visit.
• Females who test positive for pregnancy, are pregnant or breastfeeding, or plan to become pregnant during the course of the study.
• Determined by the Investigator to be inappropriate for the study.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Davita Clinical Research

INDUSTRY

Sponsor Role: collaborator

RAI Services Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elizabeth Yoon, FNP-C

Role: PRINCIPAL_INVESTIGATOR

Davita Clinical Research

Locations

DaVita Clinical Research

Lakewood, Colorado, United States

Countries

United States

References

St Charles FK, Kabbani AA, Borgerding MF. Estimating tar and nicotine exposure: human smoking versus machine generated smoke yields. Regul Toxicol Pharmacol. 2010 Feb;56(1):100-10. doi: 10.1016/j.yrtph.2009.08.011. Epub 2009 Aug 31.

Reference Type: BACKGROUND

PMID: 19723554 (View on PubMed)

Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012 Jan;14(1):75-8. doi: 10.1093/ntr/ntr137. Epub 2011 Oct 24. No abstract available.

Reference Type: BACKGROUND

PMID: 22025545 (View on PubMed)

Shepperd CJ, St Charles FK St, Lien M, Dixon M . Validation of methods for determining consumer smoked cigarette yields from cigarette filter analysis. Beitr Tabakforsch Int. 2006;22:176-184.

Reference Type: BACKGROUND

Other Identifiers

CSD1603

Identifier Type: -

Identifier Source: org_study_id